Neratinib for ERBB2 mutant, HER2 non-amplified, metastatic breast cancer: Preliminary analysis from a multicenter, open-label, multi-histology phase II basket trial Meeting Abstract
| Authors: | Hyman, D. M.; Piha-Paul, S. A.; Rodón, J.; Saura, C.; Puzanov, I.; Shapiro, G. I.; Loi, S.; Joensuu, H.; Hanrahan, A. J.; Modi, S.; Lalani, A. S.; Xu, F.; Garza, S. J.; Cutler, R. E.; Bryce, R.; Meric-Bernstam, F.; Baselga, J.; Solit, D. B. |
| Abstract Title: | Neratinib for ERBB2 mutant, HER2 non-amplified, metastatic breast cancer: Preliminary analysis from a multicenter, open-label, multi-histology phase II basket trial |
| Meeting Title: | 38th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) |
| Journal Title: | Cancer Research |
| Volume: | 76 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2015 Dec 8-12 |
| Meeting Location: | San Antonio, TX |
| ISSN: | 0008-5472 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2016-02-15 |
| Language: | English |
| ACCESSION: | WOS:000375622401290 |
| DOI: | 10.1158/1538-7445.sabcs15-pd5-05 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: PD5-05 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work